The administration of donor NK cells together with IL-2 and with the TGF-β receptor I inhibitor, vactosertib, is being trialed in relapsed patients with solid and liquid cancers, including MDS (NCT05400122). This evidence concerns the gene IL2 and myelodysplastic syndrome.